Market Cap 84.51M
Revenue (ttm) 0.00
Net Income (ttm) -22.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 370,700
Avg Vol 767,924
Day's Range N/A - N/A
Shares Out 60.80M
Stochastic %K 35%
Beta 0.23
Analysts Sell
Price Target $14.00

Company Profile

MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Industry: Biotechnology
Sector: Healthcare
Phone: 312 416 8592
Address:
444 West Lake Street, Suite 1700, Chicago, United States
telomerase
telomerase Jun. 25 at 6:36 PM
$MAIA https://x.com/MAIABiotech/status/2070162817823437092
0 · Reply
GISBlaster98
GISBlaster98 Jun. 25 at 4:27 PM
$MAIA …News out …MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
0 · Reply
beforethedeluge
beforethedeluge Jun. 25 at 3:05 PM
$MAIA This stock is caught in a slough of despond.
2 · Reply
DAWGNuts
DAWGNuts Jun. 25 at 2:15 PM
$MAIA I think this could be a rising tide lifts all boats scenario. Any positive news from the telomerase/telomere space and this should climb. Knowing that I think a round of dilution could be at a much higher price, if dilution comes at all. What's to say they don't make a deal before hand? A measly $1B offer from BP would be a 10 bagger for mngmt.
0 · Reply
FetchDog
FetchDog Jun. 24 at 2:57 PM
$MAIA The chart looks great for bulls, at least for the near term. The heavy volume candles (15 minute scale, for example) since June 10 are all green. On the daily we see various cups forming potential upside. However, their press release of June 4 has me worried. For their pivotal Phase 3 trial, THIO-104, they state that they are "targeting up to 100 patients by year-end and expect to have sufficient survival data to conduct an interim analysis in 2027. I think that means survival data in late 2027. They need to raise more capital by around december, and they will be a long way from enrollment or meaningful data at that time. As people see the cash running low, I believe the stock price will likely drift down significantly. They will need significantly more capital. Dilution is coming. I sold my modest position today at $1.48 for a reasonable profit. I'll wait for a lower price.
5 · Reply
LabPsycho
LabPsycho Jun. 23 at 7:36 PM
$MAIA @synaphai What an outstanding, objective post. Thank you for your insight and contribution. So you were not lulled by the title of one of their recent data updates with "$50 billion" in it - Ha. That type of thing should never be the header for a data release, rather a capsule summary of the results is what the title should be about) And yeah, the 99% predicted probability success rate is outrageous and nonsense. They would be better off without all of these over the top, irrational and or misleading (IMO) sentences / claims, etc. However, one can not get away with that bs with an NIH grant application (which they have). They are actually moving along with Phase 3 (these guys dont seem to be slackers) and The Roche and REGN (collaborations not partnerships) are encouraging, but until someone coughs up real $$$ for a partnership, credibility is strained. Doesn't mean it cant run 300%.
0 · Reply
LabPsycho
LabPsycho Jun. 23 at 7:28 PM
$MAIA @LEVF_4_the_win The idea I proposed, and even illustrated with chat's help (for the image, not the idea) shows the patient receiving both the Ab and THIO simultaneously - potentially promoting the formation of the ADC in situ. Only a modest adjustment to the protocol would be required - a simple amendment. Furthermore, before that, the simple lab test I described to test feasibility would cost almost nothing (maybe $1000 in supplies at most + a day ) an experienced post-doc could do the study in a day.
1 · Reply
MoneyHelix
MoneyHelix Jun. 23 at 6:15 PM
$MAIA Pfizer's Phase 3 NSCLC trial failed to meet its OS target. Sad outcome for patients, but incredible news for MAIA 🥂 The value of MAIA's pipeline continues to grow as more clinical trials fail and MAIA succeeds 🥂
1 · Reply
LabPsycho
LabPsycho Jun. 23 at 4:18 PM
$MAIA @GISBlaster98 Looks like going to need either a small molecule or slightly larger PROTAC type degrader to target solid tumors
0 · Reply
Stacey313
Stacey313 Jun. 23 at 3:42 PM
$MAIA BP will write that check.
1 · Reply
Latest News on MAIA
MAIA Biotechnology Transcript: AGM 2026

May 21, 2026, 11:00 AM EDT - 5 weeks ago

MAIA Biotechnology Transcript: AGM 2026


MAIA Biotechnology Proxy statement: Proxy filing

May 19, 2026, 8:00 AM EDT - 5 weeks ago

MAIA Biotechnology Proxy statement: Proxy filing


MAIA Biotechnology Quarterly report: Q1 2026

May 11, 2026, 7:00 AM EDT - 6 weeks ago

MAIA Biotechnology Quarterly report: Q1 2026


MAIA Biotechnology Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

MAIA Biotechnology Proxy statement: Proxy filing


MAIA Biotechnology Proxy statement: Proxy filing

Apr 7, 2026, 8:00 AM EDT - 2 months ago

MAIA Biotechnology Proxy statement: Proxy filing


MAIA Biotechnology Proxy statement: Proxy filing

Apr 7, 2026, 8:00 AM EDT - 2 months ago

MAIA Biotechnology Proxy statement: Proxy filing


MAIA Biotechnology Annual report: Q4 2025

Mar 23, 2026, 7:00 AM EDT - 3 months ago

MAIA Biotechnology Annual report: Q4 2025


MAIA Biotechnology 20M share Spot Secondary priced at $1.50

2026-03-03T10:20:12.000Z - 4 months ago

MAIA Biotechnology 20M share Spot Secondary priced at $1.50


MAIA Biotechnology published a 2026 Letter to Shareholders

2026-02-24T13:50:43.000Z - 4 months ago

MAIA Biotechnology published a 2026 Letter to Shareholders


MAIA Biotechnology highlights milestones, catalysts for FY26

2026-01-20T15:25:23.000Z - 5 months ago

MAIA Biotechnology highlights milestones, catalysts for FY26


MAIA Biotechnology announces $1.51M private placement

2025-12-16T21:21:06.000Z - 6 months ago

MAIA Biotechnology announces $1.51M private placement


MAIA Biotechnology Announces $1.51 Million Private Placement

Dec 16, 2025, 4:15 PM EST - 6 months ago

MAIA Biotechnology Announces $1.51 Million Private Placement


MAIA Biotechnology CEO, board members acquire company shares

2025-12-11T13:30:33.000Z - 7 months ago

MAIA Biotechnology CEO, board members acquire company shares


MAIA Biotechnology CEO presents at Smart Diaspora 2025

2025-11-20T13:55:24.000Z - 7 months ago

MAIA Biotechnology CEO presents at Smart Diaspora 2025


MAIA Biotechnology Quarterly report: Q3 2025

Nov 7, 2025, 4:00 PM EST - 8 months ago

MAIA Biotechnology Quarterly report: Q3 2025


MAIA Biotechnology Announces $736,600 Private Placement

Oct 13, 2025, 4:20 PM EDT - 9 months ago

MAIA Biotechnology Announces $736,600 Private Placement


MAIA Biotechnology to initiate digital asset treasury strategy

2025-10-07T13:01:04.000Z - 9 months ago

MAIA Biotechnology to initiate digital asset treasury strategy


MAIA Biotechnology Announces $2.25 Million Private Placement

Sep 29, 2025, 4:30 PM EDT - 9 months ago

MAIA Biotechnology Announces $2.25 Million Private Placement


MAIA Biotechnology Quarterly report: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 11 months ago

MAIA Biotechnology Quarterly report: Q2 2025


MAIA Biotechnology Quarterly report: Q1 2025

May 9, 2025, 4:00 PM EDT - 1 year ago

MAIA Biotechnology Quarterly report: Q1 2025


MAIA Biotechnology Announces $1.08 Million Private Placement

May 5, 2025, 4:05 PM EDT - 1 year ago

MAIA Biotechnology Announces $1.08 Million Private Placement


MAIA Biotechnology Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

MAIA Biotechnology Proxy statement: Proxy Filing


MAIA Biotechnology Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

MAIA Biotechnology Proxy statement: Proxy Filing


MAIA Biotechnology Proxy statement: Proxy Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

MAIA Biotechnology Proxy statement: Proxy Filing


MAIA Biotechnology Annual report: Q4 2024

Mar 20, 2025, 7:00 PM EDT - 1 year ago

MAIA Biotechnology Annual report: Q4 2024


telomerase
telomerase Jun. 25 at 6:36 PM
$MAIA https://x.com/MAIABiotech/status/2070162817823437092
0 · Reply
GISBlaster98
GISBlaster98 Jun. 25 at 4:27 PM
$MAIA …News out …MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
0 · Reply
beforethedeluge
beforethedeluge Jun. 25 at 3:05 PM
$MAIA This stock is caught in a slough of despond.
2 · Reply
DAWGNuts
DAWGNuts Jun. 25 at 2:15 PM
$MAIA I think this could be a rising tide lifts all boats scenario. Any positive news from the telomerase/telomere space and this should climb. Knowing that I think a round of dilution could be at a much higher price, if dilution comes at all. What's to say they don't make a deal before hand? A measly $1B offer from BP would be a 10 bagger for mngmt.
0 · Reply
FetchDog
FetchDog Jun. 24 at 2:57 PM
$MAIA The chart looks great for bulls, at least for the near term. The heavy volume candles (15 minute scale, for example) since June 10 are all green. On the daily we see various cups forming potential upside. However, their press release of June 4 has me worried. For their pivotal Phase 3 trial, THIO-104, they state that they are "targeting up to 100 patients by year-end and expect to have sufficient survival data to conduct an interim analysis in 2027. I think that means survival data in late 2027. They need to raise more capital by around december, and they will be a long way from enrollment or meaningful data at that time. As people see the cash running low, I believe the stock price will likely drift down significantly. They will need significantly more capital. Dilution is coming. I sold my modest position today at $1.48 for a reasonable profit. I'll wait for a lower price.
5 · Reply
LabPsycho
LabPsycho Jun. 23 at 7:36 PM
$MAIA @synaphai What an outstanding, objective post. Thank you for your insight and contribution. So you were not lulled by the title of one of their recent data updates with "$50 billion" in it - Ha. That type of thing should never be the header for a data release, rather a capsule summary of the results is what the title should be about) And yeah, the 99% predicted probability success rate is outrageous and nonsense. They would be better off without all of these over the top, irrational and or misleading (IMO) sentences / claims, etc. However, one can not get away with that bs with an NIH grant application (which they have). They are actually moving along with Phase 3 (these guys dont seem to be slackers) and The Roche and REGN (collaborations not partnerships) are encouraging, but until someone coughs up real $$$ for a partnership, credibility is strained. Doesn't mean it cant run 300%.
0 · Reply
LabPsycho
LabPsycho Jun. 23 at 7:28 PM
$MAIA @LEVF_4_the_win The idea I proposed, and even illustrated with chat's help (for the image, not the idea) shows the patient receiving both the Ab and THIO simultaneously - potentially promoting the formation of the ADC in situ. Only a modest adjustment to the protocol would be required - a simple amendment. Furthermore, before that, the simple lab test I described to test feasibility would cost almost nothing (maybe $1000 in supplies at most + a day ) an experienced post-doc could do the study in a day.
1 · Reply
MoneyHelix
MoneyHelix Jun. 23 at 6:15 PM
$MAIA Pfizer's Phase 3 NSCLC trial failed to meet its OS target. Sad outcome for patients, but incredible news for MAIA 🥂 The value of MAIA's pipeline continues to grow as more clinical trials fail and MAIA succeeds 🥂
1 · Reply
LabPsycho
LabPsycho Jun. 23 at 4:18 PM
$MAIA @GISBlaster98 Looks like going to need either a small molecule or slightly larger PROTAC type degrader to target solid tumors
0 · Reply
Stacey313
Stacey313 Jun. 23 at 3:42 PM
$MAIA BP will write that check.
1 · Reply
JRobb66
JRobb66 Jun. 23 at 10:54 AM
$MAIA I have a question, what % of patients with advanced NCSLC make it to 3rd line?
1 · Reply
GISBlaster98
GISBlaster98 Jun. 22 at 11:30 PM
$MAIA Interesting take…
0 · Reply
GISBlaster98
GISBlaster98 Jun. 22 at 10:03 PM
$MAIA https://www.reuters.com/business/healthcare-pharmaceuticals/pfizers-experimental-drug-misses-main-goal-lung-cancer-trial-2026-06-22/
0 · Reply
LabPsycho
LabPsycho Jun. 22 at 9:03 PM
$MAIA @Chemaster What they need is a biochemical genius who can parlay THIO into a REGN partnership by proposing a joint venture to develop an ADC with MAIAs THIO and Regeneron's Libtayo® Antibody...oh wait...they already have that here...gifted to them for FREE, by me, and I not on their payroll! And I even described a simple, proof of concept experiment they could do in ONE Day in just about any immunological / biochemical research lab to test the feasibility - for cheap! Hello? What is it going to take?. @telomerase @MAIA @DSCallez @redfox43202
2 · Reply
signaljumper
signaljumper Jun. 22 at 6:58 PM
$MAIA a Close above 1.50 and we change from sideways to bullish mode
1 · Reply
Channelchek
Channelchek Jun. 22 at 5:10 PM
Noble Capital Markets Research Report: MAIA Biotechnology ($MAIA) – Stream Of Clinical Milestones Reported In June Shows Ateganosine Progress Strong Progress Reported In Both Clinical Trials. MAIA currently has two clinical trials in progress. Both trials are testing the combination of ateganosine (aka THIO) and the checkpoint inhibitor cemiplimab (Libtayo, from Regeneron) as a third-line treatment for advanced non-small cell lung cancer (NSCLC). During June, MAIA opened two additional clinical sites for Phase 2 and reported strong enrollment progress in Phase 3. Read full report here: https://www.channelchek.com/news-channel/maia-biotechnology-maia-stream-of-clinical-milestones-reported-in-june-shows-ateganosine-progress
0 · Reply
LabPsycho
LabPsycho Jun. 21 at 11:44 PM
$MAIA Has anyone actually combed over their recent poster publications and tried to reconcile the data with their press releases?
1 · Reply
DSCallez
DSCallez Jun. 19 at 10:41 AM
$MAIA I have a question for the experienced folks here, like @LabPsycho , @telomerase, or others. I’m thinking about investing, but I’ve only been following the stock casually. The Phase 2 trial in third-line patients showed a very good median overall survival (mOS) of 17 months, which is why MAIA itself says the probability of success is 99% in Phase 3. But I seem to recall that in second-line patients, the mOS was only 12 months. That data has since been buried. I can’t find it anymore. What makes you confident that we can rely more on the Phase 2 data from the third-line trial rather than the second-line trial? Both had small sample sizes.
8 · Reply
LabPsycho
LabPsycho Jun. 18 at 4:24 PM
$MAIA - I really don't want to post a "Day 6 Positive Development, Fizz 6.0" later today... Have to give credit to the MAIA team however - they seem to know how to husstle (both ways - lol). It ain't easy getting all the documentation in place and legal signoffs, Instutional Review Board Approval, etc. required for getting these clinicals going.
1 · Reply
MoneyHelix
MoneyHelix Jun. 18 at 3:35 PM
$MAIA MAIA is executing with precision, accuracy, and speed, and they have the War Chest needed to keep pushing forward. I was not expecting US sites to open this fast 🥂 what a great surprise.
0 · Reply
GISBlaster98
GISBlaster98 Jun. 18 at 12:31 PM
$MAIA Press Release today…CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the third U.S. clinical site in its Phase 2 THIO-101 expansion trial, Winship Cancer Institute of Emory University (“Winship”), is activated and now enrolling patients. The trial studies MAIA’s lead investigational telomere-targeting agent, ateganosine, as a third-line (3L) treatment for non-small cell lung cancer (NSCLC).
1 · Reply
telomerase
telomerase Jun. 17 at 4:37 PM
$MAIA So the question of the day is... SPCX puts, or SSPC inverse ETF?
1 · Reply